Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
37
pubmed:dateCreated
2003-9-8
pubmed:abstractText
We hypothesized that glucose-mediated alterations in vascular smooth muscle cell signal transduction contribute to diabetic complications. We found enhanced AngII activation of Akt and extracellular ERK1/2 in vascular smooth muscle cells incubated with high glucose (27.5 mM) compared with low glucose (5.5 mM). Because AngII-mediated transactivation of the epidermal growth factor receptor (EGFR) is important in Akt and ERK1/2 activation, we studied the effects of glucose on EGFR function. The EGFR in cells cultured for 48 h in low glucose was smaller (145 kDa) than the EGFR in cells cultured with high glucose (170 kDa). The shift from the 170-kDa isoform to the 145-kDa isoform was reversible and dependent upon glucose concentration with EC50 approximately 1 mM. N-Glycosylation was responsible because peptide N-glycosidase F treatment of isolated 170-kDa EGFR yielded a single band at 145 kDa. Cell surface biotinylation showed that the 145-kDa EGFR was present on plasma membrane. AngII and other G-protein-coupled receptor ligands known to transactivate EGFR phosphorylated the 170-kDa EGFR but not the 145-kDa EGFR, whereas EGF, heparin-binding EGF-like growth factor, and transforming growth factor-alpha phosphorylated both receptors. Subcellular fractionation showed that the 145-kDa receptor localized to a different plasma membrane domain than the 170-kDa receptor. These results establish a novel mechanism by which glucose-dependent EGFR N-glycosylation modulates AngII signal transduction and suggest a potential mechanism for pathogenic effects of AngII in diabetic vasculopathy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0021-9258
pubmed:author
pubmed:issnType
Print
pubmed:day
12
pubmed:volume
278
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
35049-56
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:12829718-Angiotensin II, pubmed-meshheading:12829718-Animals, pubmed-meshheading:12829718-Aorta, Thoracic, pubmed-meshheading:12829718-Glucose, pubmed-meshheading:12829718-Glycosylation, pubmed-meshheading:12829718-Kinetics, pubmed-meshheading:12829718-Male, pubmed-meshheading:12829718-Mitogen-Activated Protein Kinase 1, pubmed-meshheading:12829718-Mitogen-Activated Protein Kinase 3, pubmed-meshheading:12829718-Mitogen-Activated Protein Kinases, pubmed-meshheading:12829718-Models, Biological, pubmed-meshheading:12829718-Molecular Weight, pubmed-meshheading:12829718-Muscle, Smooth, Vascular, pubmed-meshheading:12829718-Phosphorylation, pubmed-meshheading:12829718-Protein-Serine-Threonine Kinases, pubmed-meshheading:12829718-Proto-Oncogene Proteins, pubmed-meshheading:12829718-Proto-Oncogene Proteins c-akt, pubmed-meshheading:12829718-Rats, pubmed-meshheading:12829718-Rats, Sprague-Dawley, pubmed-meshheading:12829718-Receptor, Epidermal Growth Factor, pubmed-meshheading:12829718-Transcriptional Activation
pubmed:year
2003
pubmed:articleTitle
Epidermal growth factor receptor transactivation is regulated by glucose in vascular smooth muscle cells.
pubmed:affiliation
Center for Cardiovascular Research, University of Rochester, Rochester, New York 14642, USA.
pubmed:publicationType
Journal Article